FeesSafety
Pluang+

Bitcoin poised to gain long-term regardless of AI boom, recession, or economic conditions, says Bitwise CIO.

Market News
15 Oct 2026, 00:31 WIB
Crypto Briefing
View Source
Bullish
Bitcoin poised to gain long-term regardless of AI boom, recession, or economic conditions, says Bitwise CIO.

Bitwise CIO Matt Hougan says Bitcoin could benefit in the long run from various economic scenarios including an AI-driven productivity boom, a recession caused by an AI market collapse, or moderate economic growth. Despite recent selling pressure due to higher US inflation and expectations of a Fed rate hike, Hougan believes Bitcoin's value will rise over time through increased institutional adoption and demand as a store of value. He also notes that different Federal Reserve policies could support Bitcoin’s growth either through economic stimulus or inflation-driven demand. However, short-term volatility is expected, and risks like government restrictions and technological threats remain.

Bitwise CIO Matt Hougan's views on Bitcoin come with Pluang's cryptocurrency market snapshot as of Oct 15, 2026 03:51 WIB. Out of 50 major cryptocurrencies priced on Pluang, 5 rose and 44 fell today. Notable movers include BAL (Balancer) with a 1-day change of +11.14% at Rp16.297, BAT (Basic Attention Token) down 12.59% at Rp3.056, and ONE (Harmony) down 9.15% at Rp28.

More News

New data shows nipocalimab improves mouth dryness in Sjögren's disease, with Phase 3 trials underway.

New data shows nipocalimab improves mouth dryness in Sjögren's disease, with Phase 3 trials underway.

Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...

Company Fundamentals
Bullish
5 hours ago
ICOTYDE shows strong Phase 3 results for psoriatic arthritis with 58% ACR20 response at 16 weeks

ICOTYDE shows strong Phase 3 results for psoriatic arthritis with 58% ACR20 response at 16 weeks

Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...

Company Fundamentals
Bullish
5 hours ago
Phase 3 ALKIVIA study shows efgartigimod improves autoimmune myositis symptoms, meeting key endpoints.

Phase 3 ALKIVIA study shows efgartigimod improves autoimmune myositis symptoms, meeting key endpoints.

The Phase 3 ALKIVIA study by argenx demonstrated that efgartigimod significantly improved symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). The study met its primary and key...

Company Fundamentals
Bullish
5 hours ago
Uber lags in robotaxi race with slow growth and weak profits, warns of value trap at current stock price.

Uber lags in robotaxi race with slow growth and weak profits, warns of value trap at current stock price.

Uber Technologies is falling behind competitors Waymo and Tesla in the U.S. robotaxi market, projecting only 2,000 robotaxis by 2027 compared to Waymo's 20,000 and Tesla's plans for millions. The company's revenue growth is slowing, with Q3 growth un...

Market News
Bearish
5 hours ago
Bitcoin mining power surpasses one zettahash as competition strengthens again

Bitcoin mining power surpasses one zettahash as competition strengthens again

Bitcoin's total mining hashrate has rebounded above one zettahash over the past week, signaling renewed strength in the network's mining competition. This recovery suggests that recent exits by some mining companies do not indicate an overall decline...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App